Clinical and epidemiological characteristics of leptospirosis in patients under and over 5 years of age in primary health centers in the Peruvian Amazon, 2022–2024 Authors: Stefano V. Davila-Philipps, Tery Vasquez Hassinger, Kary K. Vela-Tello, Jorge I. Carrasco-Celi, Yoki N. Rios-Alava, James L. Vasquez-Lechuga, Marcos H. Parimango-Alvarez, Johan Marin-Lizarraga, Edgar A. Ramirez-García, Karine Zevallos, Stuart D. Blacksell, Yung-Fu Chang, Stuart D. Blacksell, Yung-Fu Chang, Stuart D. Blacksell, Yung-Fu Chang, Stuart D. Blacksell, Yung-Fu Chang Published: 2026 ABSTRACT BackgroundLeptospirosis is an emerging zoonotic disease with high incidence in tropical regions such as the Peruvian Amazon. Although it affects individuals of all ages, knowledge about its clinical and epidemiological profile in children under 5 years remains limited. In this age group, leptospirosis may present with nonspecific manifestations, which may hinder timely recognition in primary care.MethodologyWe conducted a retrospective cross-sectional study using secondary data from medical records and epidemiological forms of MAT-confirmed leptospirosis cases evaluated between 2022 and 2024 at four primary health care centers in Belén, Loreto, Peru. A total of 2,325 patients with clinical suspicion of leptospirosis were evaluated during the study period, of whom 400 MAT-confirmed cases with sufficient information for analysis were included. Comparisons between patients under 5 years and those aged 5 years or older were exploratory.ResultsAmong the 400 confirmed cases, 28 occurred in children under 5 years. In this age group, the most frequently recorded symptoms were malaise (78.6%) and fever (71.4%). Half of the children under 5 years lived in flood-prone areas, and 46.4% were evaluated within the first 3 days after symptom onset. Compared with older patients, children under 5 years more often showed nonspecific symptom profiles, whereas headaches and chills were less frequently recorded. Nutritional classification and selected symptom patterns also differed between age groups, although these comparisons were exploratory and based on a small pediatric sample.ConclusionIn this series of MAT-confirmed leptospirosis cases managed at the primary health care centers, children under 5 years commonly presented with nonspecific symptoms such as malaise and fever. In an endemic Amazonian setting where multiple febrile illnesses coexist, this pattern may hinder early recognition. These findings support the need to strengthen clinical suspicion, diagnostic capacity, and epidemiological surveillance for pediatric leptospirosis in primary care. Further studies with larger pediatric samples are needed to better characterize age-related differences in presentation. Introduction Leptospirosis is a globally distributed zoonotic disease caused by spirochete bacteria of the genus Leptospira, with a wide clinical spectrum ranging from subclinical infection to severe disease with multiorgan failure. Transmission to humans occurs through direct or indirect exposure to urine from infected wild or domestic animals, particularly rodents, dogs, pigs, and cattle. In reservoir hosts, Leptospira colonizes the proximal renal tubules and is excreted in urine, contaminating soil and water. In settings with inadequate sanitation, frequent flooding, and precarious housing, these environmental conditions favor bacterial persistence and increase the risk of human exposure [1,2]. Leptospira has worldwide distribution, with the highest incidence in tropical and subtropical regions, where it contributes substantially to febrile illness morbidity and mortality. Regions with the greatest estimated burden include Sub-Saharan Africa, Latin America and the Caribbean, South and Southeast Asia, and Oceania. Global incidence exceeds one million cases annually, with approximately 60,000 deaths [3]. In the Peruvian Amazon, leptospirosis is endemic, with epidemic surges occurring after periods of heavy rainfall and flooding. In Loreto, outbreaks and increased transmission have been documented in association with Amazon River overflows, and national and regional surveillance in 2023 reported a marked increase in cases in Loreto during the post-rainy season, including outbreak investigations in affected localities. El Niño-related rainfall and flooding events in Peru have likewise been associated with increased leptospirosis transmission [4,5]. As of epidemiological week 52 of 2024, Peru had reported 9,520 leptospirosis cases, an incidence of 27.91 per 100,000 inhabitants, and 16 confirmed deaths, with a substantial proportion concentrated in high-burden Amazonian departments, particularly Loreto, Ayacucho, Madre de Dios, and Ucayali [6]. In this high-burden setting, where many suspected cases are initially assessed outpatient primary-care settings, understanding age-stratified clinical profiles is relevant to improve early clinical suspicion, guide targeted diagnostic testing, and support timely treatment [7]. Age has been associated with clinically meaningful differences in leptospirosis presentation and outcomes. Early manifestations are often nonspecific and overlap with other causes of acute febrile illness in tropical settings, including dengue, malaria, rickettsial infections, and bacterial sepsis, which may delay recognition and appropriate management. Defining age-stratified clinical profiles may therefore help strengthen early clinical suspicion in endemic areas [8–11]. Classic severe manifestations may be less frequently observed in pediatric patients than in adults, but they may also present with more nonspecific or atypical patterns that are harder to recognize in primary health care centers [12,13]. In early childhood, clinical assessment may be complicated by limited self-reporting of subjective symptoms, and children with leptospirosis may less frequently exhibit the classic severe features seen in adults, such as jaundice and overt renal dysfunction, thereby reducing early diagnostic suspicion at the first point of care [13–16]. Belén, a district of Maynas Province in Loreto, experiences seasonal river flooding, inadequate sanitation, precarious housing, and limited access to safe water, all of which create favorable conditions for leptospirosis transmission. These environmental and social conditions make Belén a priority area for leptospirosis surveillance and public health intervention. Although leptospirosis has been extensively described in general populations, relatively few studies have systematically compared clinical and epidemiological differences across age groups, particularly in outpatient or primary health care centers and among children under 5 years of age. This gap is especially relevant in the Peruvian Amazon, where early presentations frequently overlap with other causes of acute febrile illness and where most suspected cases are managed initially at the first level of care. Therefore, this study aimed to describe and compare the clinical manifestations and epidemiological characteristics of confirmed leptospirosis cases in patients under 5 years and those aged 5 years or older evaluated at four primary health care centers in Belén, Loreto. By defining age-stratified outpatient profiles in this setting, the findings may inform prevention strategies and support diagnostic suspicion and initial clinical decision-making at the primary health care centers. Methods Ethics statement The study was approved by the Ethics Committee of the Regional Hospital of Loreto “Felipe Santiago Arriola Iglesias” (No. 091-CIE-HRL-2024). This was a retrospective study based on routinely collected clinical records. All data were de-identified prior to analysis and were handled in accordance with institutional policies to protect confidentiality, with access restricted to the study team. The ethics committee granted a waiver of informed consent because the study used existing medical records, posed minimal risk to participants, and did not involve direct contact with patients. Study design This was a retrospective cross-sectional study using secondary data from clinical records of patients with Microscopic Agglutination Test (MAT) confirmed leptospirosis treated at four primary health care centers in the district of Belén, Maynas Province, Loreto region, Peru, between January 1, 2022, and December 31, 2024. The study was designed as a descriptive and exploratory analysis; therefore, no a priori confirmatory hypothesis was tested. Study setting The study was conducted in four first-level Ministry of Health primary health care centers serving Belén and nearby urban and urban-marginal sectors of Iquitos: 6 de Octubre health center, 9 de Octubre health center, Cardozo health center, and Belén health center (Fig 1). These facilities provide primary care in areas characterized by high population density, frequent flooding, and environmental conditions favorable to tropical infectious diseases. 6 de Octubre health center is a category I-3 health center that also provides 24-hour emergency services and participates in epidemiological surveillance, whereas the other participating centers provide routine first-level care, generally with more limited emergency coverage. These differences in service organization and catchment characteristics should be considered when interpreting the distribution of confirmed cases across centers. Geographic location of the study area and included primary health centers in Loreto, Peru. Belén is a district of the province of Maynas, Loreto region, in the northeastern Peruvian Amazon. It is among the most socially and environmentally vulnerable urban areas of Iquitos, with an estimated population of approximately 76,000 inhabitants, around 75% of whom live in flood-prone areas, particularly in the lower part of the district along the Itaya River. The area has a warm, humid, rainy tropical climate, with temperatures ranging from 17°C to 38°C and annual rainfall exceeding 2,600 mm [17]. During seasonal river flooding, many households become partially submerged, creating unsanitary conditions due to water stagnation, inadequate waste disposal and limited sanitation infrastructure. These conditions increase exposure to contaminated water and other environmental hazards, facilitating the transmission of infectious diseases. Children under 5 years of age in Loreto also bear a high burden of other common conditions, including anemia, acute respiratory infections, diarrheal disease, and parasitic infections [18–20]. In this context, the environmental and social conditions of Belén, including seasonal flooding, limited access to potable water, inadequate sanitation, and precarious housing, may facilitate leptospirosis transmission and support the need for surveillance and public health interventions. Population and sample The study population consisted of patients evaluated for suspected leptospirosis at four primary health care centers in Belén during the study period. A total of 2,325 patients with clinical suspicion of leptospirosis were identified. Of these, 1,920 were excluded because leptospirosis was not confirmed by MAT, either due to a negative result or because the test was not performed, and 5 additional records were excluded because they contained insufficient information for analysis. The final analytical sample included 400 patients with MAT-confirmed leptospirosis (Fig 2). No formal sample size calculation was performed because the study included all eligible MAT-confirmed cases with sufficient information during the study period. Therefore, subgroup comparisons, particularly those involving children under 5 years of age, should be interpreted as exploratory. Flow diagram of the inclusion and exclusion of patients with suspected leptospirosis evaluated at four primary health centers. Patients were eligible for inclusion if they had a MAT-confirmed diagnosis of leptospirosis and sufficient information in the medical records and epidemiological forms for the variables included in the analysis. Confirmatory diagnosis was based on MAT performed at the National Institute of Health laboratory in Lima. A case was considered confirmed when a single serum sample showed a MAT titer of at least 1:800, with serogroup reactivity recorded. This threshold was selected in accordance with the Peruvian National Technical Health Standard for leptospirosis, which indicates that, when paired sera are not available, a single MAT titer ≥1:800 may confirm the diagnosis in the Peruvian Amazon [21]. Given the retrospective nature of this primary care study, paired acute and convalescent samples were not routinely available for all patients. Procedure and data collection Data were collected from medical records of patients with confirmed leptospirosis and from the Clinical-Epidemiological Research Form for Leptospirosis included in the Technical Health Standard for the Comprehensive Care of People Affected by Leptospirosis. Extracted variables included sociodemographic, clinical, nutritional, laboratory, and treatment-related information. Patients were categorized into two age groups: under 5 years and 5 years or older. Sociodemographic variables included sex, district of origin, type of area of residence (rural, urban, or urban-marginal), and residence in a flood-prone area. Flood-prone residence was defined based on self-report recorded in clinical or epidemiological forms and referred to living in an area affected by rainfall-related flooding and/or seasonal river overflow. Clinical variables included recorded signs and symptoms at presentation and time from symptom onset to consultation at the primary health center. Treatment variables included antibiotics, antipyretics, intravenous hydration, and other medications recorded in the chart. Laboratory variables included MAT serogroup reactivity. Nutritional status was classified using age-standardized anthropometric criteria in accordance with World Health Organization recommendations. In children under 5 years of age, undernutrition was defined as a weight-for-height Z score (WHZ) below −2 standard deviations. In children and adolescents aged 5–18 years, undernutrition was defined as a body mass index-for-age Z score (BAZ) below −2. In adults aged 19 years or older, undernutrition was defined as a body mass index (BMI) <18.5 kg/m² [22,23]. Statistical analysis Data were entered into Microsoft Excel (Windows 10 version) and analyzed using IBM SPSS Statistics version 27.0 (Windows 11). Descriptive statistics were used to summarize sociodemographic, clinical, and epidemiological variables. Categorical variables are presented as absolute and relative frequencies (n, %). Clinical and epidemiological variables were analyzed as categorical variables. Time from symptom onset to consultation was summarized using predefined categories and, for bivariate comparisons, was additionally dichotomized as ≤3 versus >3 days. Comparisons between age groups (<5 vs ≥ 5 years) were conducted using Fisher’s exact test because several variables had small cell counts. Variables included in the bivariate analysis were selected based on clinical relevance and frequency observed in the descriptive analysis. All bivariate comparisons, including variables not shown in the main text, are presented in S2 Table. Given that these analyses were exploratory and multiple variables were assessed, no formal correction for multiple testing was applied. Accordingly, p-values were interpreted as descriptive measures of statistical evidence rather than confirmatory tests of association, and no causal or definitive age-related inferences were made. Exploratory bivariate comparisons were retained to identify potential age-related clinical patterns that may inform future analytical studies. Records with insufficient information for the variables included in the analysis were excluded before statistical analysis. All tests were two-sided, and p < 0.05 was used as the nominal threshold for statistical significance. Spatial analysis A descriptive spatial analysis was conducted using geographic information systems (GIS). A reference map was created to contextualize the study area within the Loreto region and Peru. The spatial distribution of confirmed leptospirosis cases was visualized using a Kernel Density Estimation (KDE) map based on the number of confirmed cases recorded at the four participating primary health centers, using a quartic kernel and a 500 m search radius. Thus, the density surface reflects the concentration of confirmed cases by reporting health center rather than patients’ area of residence. Participating health centers were represented as geographic reference points. Base cartography was obtained from OpenStreetMap, and satellite imagery from Esri World Imagery. Spatial processing was performed in QGIS version 3.44.7 using the projected coordinate system UTM Zone 18S. Results There were 81 cases in 2022 (20.3%), 105 cases in 2023 (26.3%), and 214 cases in 2024 (53.5%) (Table 1). Thus, a higher number of confirmed cases were identified in records in 2024 than in prior years. However, as this was a retrospective review and the number of suspected cases evaluated was not available by year, these differences should not be interpreted as annual changes in incidence. Among children under 5 years, most confirmed cases were recorded in 2024 (20/28, 71.4%), whereas among patients aged 5 years or older, 194/372 (52.2%) were recorded in the same year. Cases were unevenly distributed across primary health centers: 6 de Octubre accounted for 288 of 400 confirmed cases (72.0%), followed by Cardozo with 71 (17.8%), 9 de Octubre with 37 (9.2%), and Belén with 4 (1.0%) (Table 1; Fig 3). Center-stratified demographic and clinical characteristics are presented in S1 Table. When monthly counts were aggregated across 2022–2024, patients aged 5 years or older showed the highest numbers of confirmed cases in March (n = 62), September (n = 49), and October (n = 40). Among children under 5 years, the total number of confirmed cases was small (n = 28), with low monthly counts throughout the year and a maximum of 5 cases in August (Fig 4). 10.1371/journal.pntd.0013473.t001Table 1Epidemiological characteristics of patients with confirmed leptospirosis evaluated at primary health centers in the Peruvian Amazon, 2022–2024.Characteristics<5 years (n = 28)≥5 years (n = 372)Total N = 400FrequencyPercentageFrequencyPercentageFrequencyPercentageCases reported in 202200.0%8121.8%8120.3%Cases reported in 2023828.6%9726.1%10526.3%Cases reported in 20242071.4%19452.2%21453.5%Sex Male1035.7%17346.5%18345.8% Female1864.3%19953.5%21754.3%District of origin Belén2796.4%36197.0%38897.0% San Juan00.0%92.4%92.3% Iquitos13.6%20.5%30.8%Health Center 6 de octubre2175.0%26771.8%28872.0% Cardozo414.3%6718.0%7117.8% Belén13.6%30.8%41.0% 9 de octubre27.1%359.4%379.2%Area of origin Urban1139.3%16343.8%17443.5% Urban-marginal517.9%11430.6%11929.8% Rural1242.9%9525.5%10726.8%Residence in flood-prone area Yes1450.0%16043.0%17443.5% No1450.0%21257.0%22656.5% Epidemiological characteristics of patients with confirmed leptospirosis evaluated at primary health centers in the Peruvian Amazon, 2022–2024. Kernel density map of MAT-confirmed leptospirosis cases reported in primary health centers in the Peruvian Amazon, 2022–2024. Monthly distribution of confirmed leptospirosis cases by age group (<5 vs ≥5 years) in primary health centers in the Peruvian Amazon, 2022–2024. Among children under 5 years, 12 (42.9%) were from rural areas, 11 (39.3%) from urban areas, and 5 (17.9%) from urban-marginal areas. Among patients aged 5 years or older, urban residence predominated (163 cases, 43.8%), followed by urban-marginal (114, 30.6%) and rural areas (95, 25.5%). Residence in flood-prone areas was reported in 14 children under 5 years (50.0%) and 160 patients aged 5 years or older (43.0%). Females accounted for 18 of 28 cases (64.3%) among children under 5 years and 199 of 372 cases (53.5%) among patients aged 5 years or older (Table 1). Overall, the most frequent interval from symptom onset to consultation was 3–6 days (183 cases, 45.8%). Among children under 5 years, the largest proportion presented within 0–3 days (13/28, 46.4%), whereas among patients aged 5 years or older, the largest proportion presented within 3–6 days (171/372, 46.0%) (Table 2). 10.1371/journal.pntd.0013473.t002Table 2Time from symptom onset to consultation among confirmed leptospirosis cases by age group (<5 vs ≥5 years) in primary health centers in the Peruvian Amazon, 2022–2024.Characteristics<5 years (n = 28)≥5 years (n = 372)Total (n = 400)FrequencyPercentageFrequencyPercentageFrequencyPercentage Duration of illness 0–3 days1346.4%9726.1%11027.5% 3–6 days1242.9%17146.0%18345.8% More than 6 days310.7%10428.0%10726.8% Time from symptom onset to consultation among confirmed leptospirosis cases by age group (<5 vs ≥5 years) in primary health centers in the Peruvian Amazon, 2022–2024. Regarding clinical presentation, the most frequently recorded symptoms in children under 5 years were malaise (22/28, 78.6%) and fever (20/28, 71.4%). Among patients aged 5 years or older, the most frequently recorded symptoms were fever (311/372, 83.6%), headache (247/372, 66.4%), malaise (190/372, 51.1%), and chills (133/372, 35.8%). Other symptoms more commonly recorded in patients aged 5 years or older included nausea/vomiting (23.1%), dizziness (22.6%), myalgia (16.4%), and musculoskeletal pain (10.2%) (Table 3). 10.1371/journal.pntd.0013473.t003Table 3Distribution of clinical symptoms among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) in primary health centers in the Peruvian Amazon, 2022–2024.Symptoms<5 years (n = 28)≥5 years (n = 372)Total (n = 400)FrequencyPercentageFrequencyPercentageFrequencyPercentageFever2071.4%31183.6%33182.8%Headache1035.7%24766.4%25764.3%General malaise2278.6%19051.1%21253.0%Chills27.1%13335.8%13533.8%Nausea/Vomiting621.4%8623.1%9223.0%Dizziness27.1%8422.6%8621.5%Myalgias414.3%6116.4%6516.3%Low back pain27.1%6016.1%6215.5%Cough621.4%4712.6%5313.3%Anorexia310.7%4812.9%5112.8%Diarrhea414.3%4411.8%4812.0%Abdominal pain310.7%4512.1%4812.0%Arthralgias27.1%379.9%399.8%Musculoskeletal pain13.6%3810.2%399.8%Asthenia27.1%369.7%389.5%Calf pain00.0%297.8%297.3%Retro-ocular pain13.6%287.5%297.3%Rash27.1%143.8%164.0%Dyspnea00.0%143.8%143.5%Constipation13.6%61.6%71.8%Precordial pain (chest pain)00.0%51.3%51.3%Oliguria13.6%30.8%41.0%Petechiae00.0%41.1%41.0%Hematuria00.0%20.5%20.5%Epistaxis00.0%20.5%20.5%Gastrointestinal bleeding00.0%10.3%10.3% Distribution of clinical symptoms among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) in primary health centers in the Peruvian Amazon, 2022–2024. The predominant MAT serogroup reactivity in both age groups was Varillal, detected in 24 of 28 children under 5 years (85.7%) and 316 of 372 patients aged 5 years or older (84.9%). Panama reactivity was identified in 2 children under 5 years (7.1%) and 5 patients aged 5 years or older (1.3%), whereas Hurstbridge reactivity was recorded only among patients aged 5 years or older (47 cases, 12.6%). Overall, 317 patients (79.3%) showed reactivity to a single serogroup, while 83 (20.8%) showed reactivity to two or more serogroups (Table 4). 10.1371/journal.pntd.0013473.t004Table 4Distribution of MAT serogroup reactivity among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) in primary health centers in the Peruvian Amazon, 2022–2024.Characteristics<5 years (n = 28)≥5 years (n = 372)Total (n = 400)FrequencyPercentageFrequencyPercentageFrequencyPercentage Serogroup Varillal2485.7%31684.9%34085.0% Hurstbridge00.0%4712.6%4711.8% Icterohaemorrhagiae27.1%4111.0%4310.8% Bratislava310.7%287.5%317.8% Copenhageni13.6%123.2%133.3% Australis13.6%71.9%82.0% Panama27.1%51.3%71.8% Autumnalis00.0%51.3%51.3% Canicola00.0%41.1%41.0% Bataviae00.0%30.8%30.8% Cynopteri13.6%20.5%30.8% Coxi00.0%10.3%10.3% Javanica00.0%10.3%10.3% Hardjo00.0%10.3%10.3% Djasiman00.0%10.3%10.3% Patients who presented one serogroup 2382.1%29479.0%31779.3% Patients who presented two serogroups or more 517.9%7821.0%8320.8% Distribution of MAT serogroup reactivity among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) in primary health centers in the Peruvian Amazon, 2022–2024. Paracetamol was the most frequently recorded antipyretic overall, administered in 303 cases (75.8%), including 17 of 28 children under 5 years (60.7%) and 286 of 372 patients aged 5 years or older (76.9%). Among antibiotics, amoxicillin was the most frequently recorded in children under 5 years (20/28, 71.4%), whereas doxycycline predominated in patients aged 5 years or older (222/372, 59.7%). Ciprofloxacin, ceftriaxone, and ampicillin were recorded only among patients aged 5 years or older, whereas erythromycin was recorded in 3 children under 5 years (10.7%) and 14 patients aged 5 years or older (3.8%). Intravenous 0.9% sodium chloride was administered in 3 children under 5 years (10.7%) and 49 patients aged 5 years or older (13.2%) (Table 5). 10.1371/journal.pntd.0013473.t005Table 5Medications recorded among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) evaluated at primary health care centers in the Peruvian Amazon, 2022–2024.Medications<5 years (n = 28)≥5 years (n = 372)Total (n = 400)FrequencyPercentageFrequencyPercentageFrequencyPercentage Antipyretics Paracetamol1760.7%28676.9%30375.8% Metamizole414.3%4712.6%5112.8% Antibiotics Doxycycline517.9%22259.7%22756.8% Amoxicillin2071.4%9525.5%11528.8% Ciprofloxacin00.0%359.4%358.8% Erythromycin310.7%143.8%174.3% Ceftriaxone00.0%102.7%102.5% Ampicillin00.0%20.5%20.5% Intravenous hydration 0.9% Sodium chloride310.7%4913.2%5213.0% Other Dimenhydrinate13.6%143.8%153.8% Medications recorded among confirmed leptospirosis cases by age group (<5 vs ≥ 5 years) evaluated at primary health care centers in the Peruvian Amazon, 2022–2024. In exploratory bivariate comparisons by age group, descriptive statistical differences were observed for headache, general malaise and chills (Table 6). Due to the small number of children under 5 years and the exploratory nature of these comparisons, p-values should be interpreted descriptively rather than as confirmatory evidence of age-related differences. Undernutrition was more frequent among children under 5 years (50.0% vs 14.8%; p < 0.001). In addition, presentations more than 3 days after symptom onset were less frequent in children under 5 years than in patients aged 5 years or older (53.6% vs 73.7%; p < 0.001). The complete set of exploratory bivariate comparisons is presented in S2 Table. 10.1371/journal.pntd.0013473.t006Table 6Exploratory bivariate comparisons of selected clinical characteristics between age group (<5 vs ≥5 years) in primary health centers in the Peruvian Amazon, 2022–2024.Variable<5 years (n = 28)≥5 years (n = 372)p-valueFrequencyPercentageFrequencyPercentageHeadache1035.7%24766.4%0.002General malaise2278.6%19051.1%0.005Chills27.1%13335.8%0.001Malnutrition1450.0%5514.8%<0.001Duration of illness >3 days1553.6%27473.7%<0.001 Exploratory bivariate comparisons of selected clinical characteristics between age group (<5 vs ≥5 years) in primary health centers in the Peruvian Amazon, 2022–2024. Discussion This study provides descriptive data on the epidemiological and clinical profile of MAT-confirmed leptospirosis in primary health care centers of the Peruvian Amazon, with emphasis on differences between children under 5 years and patients aged 5 years or older. Despite the limited pediatric sample, this study provides rare primary-care data on MAT-confirmed pediatric leptospirosis in a hyperendemic Amazonian setting, where outpatient presentations are underrepresented in the literature. We observed a seasonal clustering of cases that coincided with the climatic cycle of Belén, including periods of river rise and intense rainfall, which likely increase environmental exposure and may contribute to sustained transmission. This context is especially relevant in Belén, where environmental vulnerability and limited sanitation may intensify exposure risks. A clearly defined seasonal pattern was not observed among children under 5 years; however, this likely reflects the small pediatric sample rather than a true absence of temporal variation. The main age-related differences observed in this primary care cohort involved symptom profile, nutritional classification, and timing of consultation. These comparisons should be viewed as exploratory given the small pediatric sample size, multiple comparisons, and retrospective facility-based data. The small number of children under 5 years limited statistical power for subgroup comparisons and increased the risk of unstable estimates; therefore, age-group comparisons should be interpreted as exploratory and hypothesis-generating rather than confirmatory. In addition, some observed differences may reflect variation in symptom ascertainment, caregiver reporting, and healthcare-seeking behavior rather than true biological differences between age groups. Accordingly, these findings are best interpreted as descriptive and exploratory, particularly for children under 5 years, and require confirmation in larger prospective pediatric cohorts. Children under 5 years most often presented with nonspecific symptoms, particularly malaise and fever, whereas headache and chills were more frequently recorded in older patients. This pattern is clinically important because it may reduce early diagnostic specificity in first-level care, especially in endemic Amazonian settings where leptospirosis overlaps with other common febrile illnesses such as dengue, malaria, and arboviral infections. In very young children, especially those who are pre-verbal, subjective symptoms are also more difficult to identify and document, which may further contribute to underrecognition. Taken together, these findings support the possibility that mild pediatric leptospirosis may be underdiagnosed in routine outpatient practice unless clinicians maintain a high index of suspicion [10,24,25]. A higher proportion of children under 5 years were evaluated within the first 3 days after symptom onset. This pattern may reflect earlier caregiver concern in young children, although the categorical structure of the available data and the retrospective design limit more detailed interpretation. Caregiver recall, documentation practices, and age-related differences in how symptoms are expressed may also have influenced these findings. Rather than indicating a definitive age-related difference in help-seeking behavior, this observation should be interpreted as a descriptive pattern that warrants further study [8,24,26]. Another notable finding was the higher frequency of undernutrition among children under 5 years. This result should be interpreted carefully because nutritional status was classified using age-specific anthropometric standards, and the retrospective design does not allow causal inference. Moreover, nutritional status in this setting may be shaped by broader social and environmental determinants, including poverty, food insecurity, inadequate sanitation, coinfections, and barriers to care, none of which were captured in the available records [24,27]. Therefore, the observed difference should not be interpreted as evidence that undernutrition independently influenced presentation or recovery, but rather as a contextual finding that may reflect underlying vulnerability in this population. From a microbiological perspective, Varillal was the predominant MAT serogroup reactivity in both age groups. Panama reactivity appeared proportionally more frequent among children under 5 years, although this observation was based on very few cases and should not be overinterpreted. Since MAT reflects serologic reactivity rather than organism-level characterization, these findings do not permit conclusions about virulence, source of infection, or age-specific susceptibility. Larger studies with broader microbiological characterization are needed to determine whether these patterns are reproducible [28]. Treatment patterns also differed by age group, with amoxicillin more frequently recorded in children under 5 years and doxycycline predominating among older patients [27]. These patterns likely reflect routine primary-care practice and age-related prescribing considerations and are broadly consistent with the Peruvian National Technical Health Standard, which recommends amoxicillin or erythromycin as oral options for mild leptospirosis in children, while doxycycline, amoxicillin, ciprofloxacin, or erythromycin are listed as oral options for adults [21]. However, because this was a retrospective review of primary care records, detailed information on severity, timing of treatment initiation, dosing, duration, adherence, and clinical outcomes was not consistently available. Accordingly, these data should be interpreted as describing local prescribing patterns rather than treatment effectiveness or adherence to guidelines [8,29]. This study reflects a predominantly ambulatory and mild clinical spectrum of leptospirosis managed at primary health care centers. Patients with warning signs or suspected severe disease may have been referred to higher levels of care and are therefore likely underrepresented. In addition, the analysis depended on routinely collected variables and MAT results reported in the medical records, which limited assessment of other potentially important determinants such as socioeconomic conditions, sanitation, coinfections, and complementary diagnostic methods. These considerations are important when interpreting the scope and generalizability of the findings. Overall, children under 5 years of age with confirmed leptospirosis in this primary care series commonly presented with nonspecific symptoms such as malaise and fever and were frequently identified in flood-prone settings. In the Amazonian context, where leptospirosis coexists with other endemic febrile illnesses, this pattern may complicate early recognition at the primary health care centers. These findings support the need to strengthen clinical suspicion, improve diagnostic capacity in primary health care centers, and reinforce epidemiological surveillance for pediatric leptospirosis in endemic areas. Further studies are needed to better characterize age-related differences in presentation and to clarify how social and environmental factors shape risk in young children. Limitations This study should be interpreted considering several limitations. Its retrospective design, based on routine medical records from primary-care facilities, restricted the completeness and standardization of key variables, including symptom documentation, timing of presentation, and treatment-related information. Symptom ascertainment may also have differed by age group, as young children may have limited ability to report subjective symptoms such as headache, myalgia, chills, dizziness, or abdominal pain, making documentation more dependent on caregiver report and clinician interpretation. The small number of confirmed cases in children under 5 years also limited statistical precision and reduced confidence in subgroup comparisons. Given that the study was conducted in primary health care centers, the findings mainly represent mild and ambulatory cases, whereas more severe presentations may have been referred to higher levels of care and thus were not fully captured. In addition, potentially relevant contextual factors, such as socioeconomic conditions, sanitation, coinfections, and adherence to treatment, were not available in the records reviewed. Although MAT is the reference serological method for leptospirosis surveillance, the use of single-sample MAT results in this retrospective setting may have limited the ability to distinguish recent infection from previous exposure or cross-reactive serological responses, and MAT serogroup reactivity should not be interpreted as definitive identification of the infecting serogroup. Although the total number of suspected cases reviewed during the study period was available, complete year-specific and center-specific denominators for suspected and tested patients were not analyzed in this study, which limits interpretation of temporal and between-center differences in confirmed case counts. Therefore, the study is best understood as a descriptive analysis of outpatient leptospirosis patterns in an endemic Amazonian setting, rather than as evidence of causal age-related differences. Supporting information Descriptive distribution of confirmed leptospirosis cases according to health facility, demographic characteristics, year of diagnosis, and reported symptoms in the Loreto region, Peru. (DOCX) Bivariate analysis of sociodemographic, clinical, and microbiological variables by age group in patients with leptospirosis, Loreto, Peru (2022–2024). (DOCX) Authorship order change statement. (DOCX) Leptospirosis- cover letter. (DOCX) Materials license terms. (DOCX) Response to reviewers. (DOCX) 13 Jan 2026 -->PNTD-D-25-01422 Differential profile of Leptospirosis in patients under and over 5 years of age in health centers of the Peruvian Amazon, 2023–2024 PLOS Neglected Tropical Diseases Dear Dr. Zevallos, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by Mar 14 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Yung-Fu Chang Academic Editor PLOS Neglected Tropical Diseases Stuart Blacksell Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments: The author states that “A case was considered confirmed when a single blood sample showed a serological titer equal to or greater than 1:800, also identifying the serological variant.” Please provide justification, preferably with a citation, why this MAT titer was selected. The author states that “A case was considered confirmed when a single blood sample showed a serological titer equal to or greater than 1:800, also identifying the serological variant.” Please provide justification, preferably with a citation, why this MAT titer was selected. State the Leptospira serovars that were used in the MAT in the methods section. At the moment, these are detailed in Table 4, but it would be helpful to have them detailed in the methods as well. State the Leptospira serovars that were used in the MAT in the methods section. At the moment, these are detailed in Table 4, but it would be helpful to have them detailed in the methods as well. How many patients had paired samples? How many patients had paired samples? Table 4 indicates that some patients were MAT-positive against 2, 3, or 4 serovars. Is this multiple positivity or cross-reactivity? Do you have the actual titers that could demonstrate superiority or the equivalence of a particular serovar in such a case? Table 4 indicates that some patients were MAT-positive against 2, 3, or 4 serovars. Is this multiple positivity or cross-reactivity? Do you have the actual titers that could demonstrate superiority or the equivalence of a particular serovar in such a case? Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: https://journals.plos.org/plosntds/s/figures 2) We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list. 3) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form. Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager. Potential Copyright Issues: i) Figure 2. Please (a) provide a direct link to the base layer of the map (i.e., the country or region border shape) and ensure this is also included in the figure legend; and (b) provide a link to the terms of use / license information for the base layer image or shapefile. We cannot publish proprietary or copyrighted maps (e.g. Google Maps, Mapquest) and the terms of use for your map base layer must be compatible with our CC BY 4.0 license. Note: if you created the map in a software program like R or ArcGIS, please locate and indicate the source of the basemap shapefile onto which data has been plotted. If your map was obtained from a copyrighted source please amend the figure so that the base map used is from an openly available source. Alternatively, please provide explicit written permission from the copyright holder granting you the right to publish the material under our CC BY 4.0 license. If you are unsure whether you can use a map or not, please do reach out and we will be able to help you. The following websites are good examples of where you can source open access or public domain maps: * U.S. Geological Survey (USGS) - All maps are in the public domain. (http://www.usgs.gov) * PlaniGlobe - All maps are published under a Creative Commons license so please cite u201cPlaniGlobe, http://www.planiglobe.com, CC BY 2.0u201d in the image credit after the caption. (http://www.planiglobe.com/?lang=enl) * Natural Earth - All maps are public domain. (http://www.naturalearthdata.com/about/terms-of-use/). Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: Are the objectives of the study clearly articulated with a clear testable hypothesis stated? The objectives are generally stated and descriptive in nature; however, a clear, testable hypothesis is not explicitly articulated, and some analyses imply hypothesis testing beyond the stated descriptive aim. Is the study design appropriate to address the stated objectives? The retrospective, primary care–based design is appropriate for descriptive purposes but is not sufficient to support some of the inferential and multivariate conclusions currently presented. Is the population clearly described and appropriate for the hypothesis being tested? The study population is clearly described and relevant to the research question; however, the very small number of children under five limits the appropriateness of age-stratified inferential analyses. Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? No. While the overall sample is reasonable, the pediatric subgroup (<5 years) is underpowered for robust statistical comparisons, multivariate modeling, and serovar-specific analyses. Were correct statistical analyses used to support conclusions? Several statistical concerns remain, including inappropriate or unstable multivariate modeling, use of chi-square tests with sparse data, lack of adjustment for multiple comparisons, and inconsistencies in variable handling. Reanalysis is required. Are there concerns about ethical or regulatory requirements being met? No major ethical concerns were identified; appropriate ethical approval is reported for retrospective use of anonymized clinical records. ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Does the analysis presented match the analysis plan? Not fully. There are inconsistencies between the described analysis plan and the analyses presented, particularly regarding the handling of key variables (e.g., duration of illness) and the use and interpretation of multivariate regression. Are the results clearly and completely presented? The results are generally well organized and descriptive; however, several findings are overinterpreted, some statistical comparisons lack sufficient context (e.g., sparse cell counts, multiple testing), and key clarifications are needed to ensure internal consistency and transparency. Are the figures (Tables, Images) of sufficient quality for clarity? Tables are generally clear, but at least one figure (the study area map) does not meet scientific publication standards and should be replaced with a properly generated GIS-based figure. ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Are the conclusions supported by the data presented? Partially. While the descriptive findings are supported by the data, several conclusions—particularly those based on multivariate analyses and serovar-specific associations—currently exceed what the data can robustly support. Are the limitations of analysis clearly described? No. The limitations section is incomplete and does not adequately address key methodological, statistical, and diagnostic constraints that affect interpretation. Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? Yes, in a general sense, particularly regarding outpatient presentations in a hyperendemic setting; however, this contribution would be clearer if interpretations were more restrained and aligned with the descriptive nature of the study. Is public health relevance addressed? Yes. The manuscript clearly highlights public health relevance, especially for primary care surveillance and early recognition in endemic regions, although some implications should be framed more cautiously. ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: Several editorial and data presentation improvements are required to enhance clarity and scientific rigor. Terminology should be standardized throughout the manuscript (e.g., correct use of “serovar/serogroup” instead of “species,” consistent age-group labeling, and accurate use of epidemiological terms such as “case counts” rather than “prevalence”). Tables should consistently report absolute numbers alongside percentages, and reference categories should be clearly stated for all statistical comparisons. The Results section would benefit from more restrained language, clearly distinguishing descriptive findings from exploratory analyses. Figure quality also requires improvement, particularly the study area map, which should be replaced with a properly generated GIS-based figure meeting scientific publication standards. Finally, the Limitations section should be expanded to transparently address methodological, statistical, and diagnostic constraints. These changes, while partly editorial, are essential for accurate interpretation and should accompany the major analytical revisions requested; therefore, the required modifications go beyond minor or purely editorial revision. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: Please see the attached document. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> Submitted filename: My Comments_PNTD-D-25-01422.pdf 1 Apr 2026 Submitted filename: Comments_PNTD-D-25-01422 REPLY TO COMMENTS 13 March 2026.docx 28 Apr 2026 -->-->PNTD-D-25-01422R1--> Differential profile of Leptospirosis in patients under and over 5 years of age in health centers of the Peruvian Amazon, 2022–2024 PLOS Neglected Tropical Diseases Dear Dr. Zevallos, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 28 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Yung-Fu Chang Academic Editor PLOS Neglected Tropical Diseases Stuart Blacksell Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX --> Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 --> Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Your manuscript's sections are not in the correct order. Please amend to the following order: Abstract, Introduction, Results, Discussion, and Methods -->Reviewers' comments: --> Reviewer's Responses to Questions --> Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The objective is now clearly stated and appropriately framed as descriptive and comparative; however, a formal testable hypothesis is still not explicitly defined. The study is better positioned as exploratory rather than hypothesis-driven. Yes. The retrospective cross-sectional design is appropriate for the stated descriptive objective of characterizing clinical and epidemiological patterns in a primary care setting, although it remains limited for causal inference. Yes. The study population is now clearly defined, including the total suspected cases and selection process, and is appropriate for the descriptive aims. However, representativeness is influenced by primary care–based sampling and uneven distribution across centers. No. While the overall sample size (n=400) is adequate for descriptive purposes, the subgroup of children under 5 years (n=28) remains underpowered for robust comparative or inferential analyses. Partially. The statistical approach has improved, including the use of Fisher’s exact test and explicit acknowledgment of exploratory analyses without multiple testing correction. However, results should still be interpreted cautiously given small cell counts, multiple comparisons, and limited power. No. Ethical approval, data anonymization, and waiver of informed consent are clearly described and appropriate for a retrospective study using routine clinical records. ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Yes, overall. The analyses presented are now consistent with the stated plan, including descriptive summaries and exploratory bivariate comparisons. The authors appropriately clarified that comparisons are exploratory and avoided overuse of multivariate modeling. Yes, for the most part. The results are clearly structured, with appropriate separation between descriptive findings and exploratory comparisons. The inclusion of supplementary tables improves transparency. However, interpretation should remain cautious given the small pediatric sample and exploratory nature of the analyses. Tables are clear and informative. Figures have improved (e.g., inclusion of a GIS-based map), but some visual elements, particularly the density map, could still be refined to better align with scientific cartographic standards and avoid potential misinterpretation. ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Yes, largely. The conclusions are now more appropriately aligned with the descriptive and exploratory nature of the study, and major overinterpretations have been addressed. Yes. The limitations section has been substantially improved and now addresses key methodological, statistical, and contextual constraints, although a few additional points could still be more explicitly stated. Yes. The manuscript clearly highlights the relevance of outpatient and pediatric presentations in a hyperendemic setting and frames the findings as contributing to improved clinical awareness and future research directions. Yes. The study effectively emphasizes implications for primary care recognition, surveillance, and management of leptospirosis in vulnerable populations within endemic regions. ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: The manuscript has been substantially improved in clarity, structure, and alignment between methods, results, and conclusions. Remaining issues are mostly minor and editorial. Terminology should be fully standardized throughout the text (e.g., consistent use of “serovar/serogroup” and uniform age-group definitions). Some sentences could benefit from minor language polishing to improve readability and precision in English. Tables are generally clear, but minor formatting adjustments (e.g., consistent reporting of percentages and reference categories) would further enhance clarity. The revised figures represent an improvement, particularly the inclusion of a GIS-based map; however, minor refinements in cartographic presentation (e.g., legend clarity and symbology) could still improve interpretability. Overall, only minor editorial adjustments are needed to finalize the manuscript for publication. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The revised version shows substantial improvement compared to the original submission. The authors have appropriately reframed the study as descriptive and exploratory, clarified the study population and denominators, improved the statistical approach (including the use of Fisher’s exact test and clearer distinction between descriptive and inferential analyses), and significantly strengthened the Limitations section. Importantly, conclusions are now more proportionate to the data and avoid prior overinterpretation. The main strengths of the study include the use of laboratory-confirmed cases, the multi-year dataset, and the focus on primary care settings, which are often underrepresented in leptospirosis research. The emphasis on young children, despite the small sample size, highlights an important gap in the literature and provides a basis for future investigation. Remaining weaknesses are relatively minor and largely editorial. These include the need for full standardization of terminology, minor improvements in clarity and English language, and small refinements in table formatting and figure presentation. While the limitations have been substantially improved, a few additional points (e.g., symptom ascertainment bias in young children and diagnostic constraints related to MAT) could be stated more explicitly, although these do not materially compromise the overall interpretation. I suggest revising the title to better reflect the descriptive and exploratory nature of the study and to avoid implying strong differential patterns that are not fully supported by the data. A more neutral and precise formulation would improve alignment between the title and the study design. My suggestion: "Clinical and epidemiological characteristics of leptospirosis in patients under and over 5 years of age in primary health centers in the Peruvian Amazon, 2022–2024" ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No --> [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. --> --> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.-->--> Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> 3 Jun 2026 Submitted filename: Response to Reviewers - May 27 2026.docx 5 Jun 2026 Dear Dr Zevallos, We are pleased to inform you that your manuscript 'Clinical and epidemiological characteristics of leptospirosis in patients under and over 5 years of age in primary health centers in the Peruvian Amazon, 2022–2024' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Yung-Fu Chang Academic Editor PLOS Neglected Tropical Diseases Stuart Blacksell Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none Dear Dr Zevallos, We are delighted to inform you that your manuscript, "Clinical and epidemiological characteristics of leptospirosis in patients under and over 5 years of age in primary health centers in the Peruvian Amazon, 2022–2024," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases